

References

1. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood*. 2017;130:1125-1131.
2. Rampal R, Verstovsek S, Devlin SM, et al. safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: A phase II study. ASH 2019. Abstract 1463.
3. Stegelmann F, Koschmieder S, Isfort S, et al. Updated results from the German MPNSG-0212 combination trial: Ruxolitinib plus pomalidomide in myelofibrosis with anemia. ASH 2019. Abstract 672.
4. Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), as monotherapy or “add-on” to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis. ASH 2019. Abstract 670.
5. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on bone marrow fibrosis and assessment of cellularity. *Haematologica*. 2005;90:1128-1132.
6. Tse C, Shomaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res*. 2008;68:3421-3248.
7. Zeuner A, Pedini F, Francesangeli F, et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. *Blood*. 2009;113:1522-1525.
8. Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. *Cell Rep*. 2013;5:1047-1059.
9. Guo J, Roberts L, Chen Z, et al. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. *PLoS One*. 2015;10:e0114363.
10. Lagares D, Santos A, Grasberger PE, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. *Sci Transl Med*. 2017;9(420).
11. Harrison CN, Garcia JS, Mesa RA, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary MF. ASH 2019. Abstract 671.
12. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor- β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat Med*. 2014;20:408-414.
13. Reblozyl [package insert]. Summit, NJ: Celgene Corporation; 2019.
14. US Food and Drug Administration. FDA approves luspatercept-aamt for anemia in adults with MDS [press release]. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds>. Accessed June 10, 2020.
15. Gerds AT, Vannucchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. ASH 2019. Abstract 557.